

October 2018

Provid presented an update on MS drug candidates in the Biotech Spotlight session at the BioNetwork 2018 conference at Laguna Niguel.

Dr. Gary Olson, Provid CEO, presented the strategy, development plans, and clinical development approach for the company's autoimmune disease platform and drug candidates (PV-267 and 2nd generation analogs) at the conference. Details are provided in the company's detailed slide deck ([link](#)).